Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate unwanted immune responses in people, increasing the chances of side effects ...

ORNL researchers developed a method to upcycle discarded plastics into high-value macromolecules, enhancing properties for ...

Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for ...

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...